Skip to main content
Top
Published in: Diabetologia 6/2006

01-06-2006 | Article

Inability of HDL from type 2 diabetic patients to counteract the inhibitory effect of oxidised LDL on endothelium-dependent vasorelaxation

Authors: L. Perségol, B. Vergès, M. Foissac, P. Gambert, L. Duvillard

Published in: Diabetologia | Issue 6/2006

Login to get access

Abstract

Aims/hypothesis

In healthy normolipidaemic and normoglycaemic control subjects, HDL are able to reverse the inhibition of vasodilation that is induced by oxidised LDL. In type 2 diabetic patients, HDL are glycated and more triglyceride-rich than in control subjects. These alterations are likely to modify the capacity of HDL to reverse the inhibition of vasodilation induced by oxidised LDL.

Subjects and methods

Using rabbit aorta rings, we compared the ability of HDL from 16 type 2 diabetic patients and 13 control subjects to suppress the inhibition of vasodilation that is induced by oxidised LDL.

Results

Oxidised LDL inhibited endothelium-dependent vasodilation (maximal relaxation [Emax]=58.2±14.6 vs 99.3±5.2% for incubation without any lipoprotein, p<0.0001). HDL from control subjects significantly reduced the inhibitory effect of oxidised LDL on vasodilatation (Emax=77.6±12.9 vs 59.5±7.7%, p<0.001), whereas HDL from type 2 diabetic patients had no effect (Emax=52.4±20.4 vs 57.2±18.7%, NS). HDL triglyceride content was significantly higher in type 2 diabetic patients than in control subjects (5.3±2.2 vs 3.1±1.4%, p<0.01) and was highly inversely correlated to Emax for oxidised LDL+HDL in type 2 diabetic patients (r=−0.71, p<0.005).

Conclusions/interpretation

In type 2 diabetes mellitus, the ability of HDL to counteract the inhibition of endothelium-dependent vasorelaxation induced by oxidised LDL is impaired and is inversely correlated with HDL triglyceride content. These findings suggest that HDL are less atheroprotective in type 2 diabetic patients than in control subjects.
Literature
1.
go back to reference Biesbroeck RC, Albers JJ, Wahl PW, Weinberg CR, Bassett ML, Bierman EL (1982) Abnormal composition of high density lipoproteins in non-insulin-dependent diabetics. Diabetes 31:126–131PubMed Biesbroeck RC, Albers JJ, Wahl PW, Weinberg CR, Bassett ML, Bierman EL (1982) Abnormal composition of high density lipoproteins in non-insulin-dependent diabetics. Diabetes 31:126–131PubMed
2.
go back to reference Taskinen MR (1992) Quantitative and qualitative lipoprotein abnormalities in diabetes mellitus. Diabetes 41(Suppl 2):12–17PubMed Taskinen MR (1992) Quantitative and qualitative lipoprotein abnormalities in diabetes mellitus. Diabetes 41(Suppl 2):12–17PubMed
3.
go back to reference Bisoendial RJ, Hoving GK, Levels JHM et al (2003) Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein. Circulation 107:2944–2948PubMedCrossRef Bisoendial RJ, Hoving GK, Levels JHM et al (2003) Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein. Circulation 107:2944–2948PubMedCrossRef
4.
go back to reference Spieker LE, Sudano I, Hurlimann D et al (2002) High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation 105:1399–1402PubMedCrossRef Spieker LE, Sudano I, Hurlimann D et al (2002) High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation 105:1399–1402PubMedCrossRef
5.
go back to reference Matsuda Y, Hirata K, Inoue N et al (1993) High density lipoprotein reverses inhibitory effect of oxidized low density lipoprotein on endothelium-dependent arterial relaxation. Circ Res 72:1103–1109PubMed Matsuda Y, Hirata K, Inoue N et al (1993) High density lipoprotein reverses inhibitory effect of oxidized low density lipoprotein on endothelium-dependent arterial relaxation. Circ Res 72:1103–1109PubMed
6.
go back to reference Halcox JP, Schenke WH, Zalos G et al (2002) Prognostic value of coronary vascular endothelial dysfunction. Circulation 106:653–658PubMedCrossRef Halcox JP, Schenke WH, Zalos G et al (2002) Prognostic value of coronary vascular endothelial dysfunction. Circulation 106:653–658PubMedCrossRef
7.
go back to reference Schachinger V, Britten MB, Zeiher AM (2000) Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 101:1899–1906PubMed Schachinger V, Britten MB, Zeiher AM (2000) Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 101:1899–1906PubMed
8.
go back to reference McVeigh GE, Brennan GM, Johnston GD et al (1992) Impaired endothelium-dependent and independent vasodilation in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 35:771–776PubMed McVeigh GE, Brennan GM, Johnston GD et al (1992) Impaired endothelium-dependent and independent vasodilation in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 35:771–776PubMed
9.
go back to reference Deckert V, Perségol L, Viens L et al (1997) Inhibitors of arterial relaxation among components of human oxidized low-density lipoproteins. Cholesterol derivatives oxidized in position 7 are potent inhibitors of endothelium-dependent relaxation. Circulation 95:723–731PubMed Deckert V, Perségol L, Viens L et al (1997) Inhibitors of arterial relaxation among components of human oxidized low-density lipoproteins. Cholesterol derivatives oxidized in position 7 are potent inhibitors of endothelium-dependent relaxation. Circulation 95:723–731PubMed
10.
go back to reference Expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III) (2001) Executive summary of The Third Report of The National Cholesterol Education Program (NCEP). JAMA 285:2486–2497CrossRef Expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III) (2001) Executive summary of The Third Report of The National Cholesterol Education Program (NCEP). JAMA 285:2486–2497CrossRef
11.
go back to reference Gowri MS, Van der Westhuysen DR, Bridges SR, Anderson JW (1999) Decreased protection by HDL from poorly controlled type 2 diabetic subjects against LDL oxidation may be due to the abnormal composition of HDL. Arterioscler Thromb Vasc Biol 19:2226–2233PubMed Gowri MS, Van der Westhuysen DR, Bridges SR, Anderson JW (1999) Decreased protection by HDL from poorly controlled type 2 diabetic subjects against LDL oxidation may be due to the abnormal composition of HDL. Arterioscler Thromb Vasc Biol 19:2226–2233PubMed
12.
go back to reference Jacobs M, Plane F, Bruckdorfer RK (1990) Native and oxidized low-density lipoproteins have different inhibitory effects on endothelium-derived relaxing factor in the rabbit aorta. Br J Pharmacol 100:21–26PubMed Jacobs M, Plane F, Bruckdorfer RK (1990) Native and oxidized low-density lipoproteins have different inhibitory effects on endothelium-derived relaxing factor in the rabbit aorta. Br J Pharmacol 100:21–26PubMed
13.
go back to reference Deckert V, Brunet A, Lantoine F et al (1998) Inhibition by cholesterol oxides of NO release from human vascular endothelial cells. Arterioscler Thromb Vasc Biol 18:1054–1060PubMed Deckert V, Brunet A, Lantoine F et al (1998) Inhibition by cholesterol oxides of NO release from human vascular endothelial cells. Arterioscler Thromb Vasc Biol 18:1054–1060PubMed
14.
go back to reference Kugiyama K, Kerns SA, Morrisett JD, Roberts R, Henry PD (1990) Impairment of endothelium-dependent arterial relaxation by lysolecithin in modified low-density lipoproteins. Nature 344:160–162PubMedCrossRef Kugiyama K, Kerns SA, Morrisett JD, Roberts R, Henry PD (1990) Impairment of endothelium-dependent arterial relaxation by lysolecithin in modified low-density lipoproteins. Nature 344:160–162PubMedCrossRef
16.
go back to reference Wever R, Stroes E, Rabelink TJ (1998) Nitric oxide and hypercholesterolemia: a matter of oxidation and reduction? Atherosclerosis 137:51–60CrossRef Wever R, Stroes E, Rabelink TJ (1998) Nitric oxide and hypercholesterolemia: a matter of oxidation and reduction? Atherosclerosis 137:51–60CrossRef
17.
go back to reference Blair A, Shaul PW, Yuhanna IS, Conrad PA, Smart EJ (1999) Oxidized low density lipoprotein displaces endothelial nitric-oxide synthase (eNOS) from plasmalemmal caveolae and impairs eNOS activation. J Biol Chem 274:32512–32519PubMedCrossRef Blair A, Shaul PW, Yuhanna IS, Conrad PA, Smart EJ (1999) Oxidized low density lipoprotein displaces endothelial nitric-oxide synthase (eNOS) from plasmalemmal caveolae and impairs eNOS activation. J Biol Chem 274:32512–32519PubMedCrossRef
18.
go back to reference Christison JK, Rye K-A, Stocker R (1995) Exchange of oxidized cholesteryl linoleate between LDL and HDL by cholesteryl ester transfer protein. J Lipid Res 36:2017–2026PubMed Christison JK, Rye K-A, Stocker R (1995) Exchange of oxidized cholesteryl linoleate between LDL and HDL by cholesteryl ester transfer protein. J Lipid Res 36:2017–2026PubMed
19.
go back to reference Mackness MI, Arrol S, Abbott C, Durrington P (1993) Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis 104:129–135PubMedCrossRef Mackness MI, Arrol S, Abbott C, Durrington P (1993) Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis 104:129–135PubMedCrossRef
20.
go back to reference Watson AD, Berliner JA, Hama SY et al (1995) Protective effect of high density lipoprotein associated paraoxonase. J Clin Invest 96:2882–2891PubMedCrossRef Watson AD, Berliner JA, Hama SY et al (1995) Protective effect of high density lipoprotein associated paraoxonase. J Clin Invest 96:2882–2891PubMedCrossRef
21.
go back to reference Watson AD, Navab M, Hama SY et al (1995) Effect of platelet-activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein. J Clin Invest 95:774–782PubMedCrossRef Watson AD, Navab M, Hama SY et al (1995) Effect of platelet-activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein. J Clin Invest 95:774–782PubMedCrossRef
22.
go back to reference Uittenbogaard A, Shaul PW, Yuhanna IS, Blair A, Smart EJ (2000) High density lipoprotein prevents oxidized low density lipoprotein-induced inhibition of endothelial nitric-oxide synthase localization and activation in caveolae. J Biol Chem 275:11278–11283PubMedCrossRef Uittenbogaard A, Shaul PW, Yuhanna IS, Blair A, Smart EJ (2000) High density lipoprotein prevents oxidized low density lipoprotein-induced inhibition of endothelial nitric-oxide synthase localization and activation in caveolae. J Biol Chem 275:11278–11283PubMedCrossRef
23.
go back to reference Drew BG, Fidge NH, Gallon-Beaumier G, Kemp BE, Kingwell BA (2004) High-density lipoprotein and apolipoprotein AI increase endothelial NO synthase activity by protein association and multisite phosphorylation. Proc Natl Acad Sci USA 101:6999–7004PubMedCrossRef Drew BG, Fidge NH, Gallon-Beaumier G, Kemp BE, Kingwell BA (2004) High-density lipoprotein and apolipoprotein AI increase endothelial NO synthase activity by protein association and multisite phosphorylation. Proc Natl Acad Sci USA 101:6999–7004PubMedCrossRef
24.
go back to reference Mineo C, Yuhanna IS, Quon MJ, Shaul PW (2003) High density lipoprotein-induced endothelial nitric-oxide synthase activation is mediated by Akt and MAP kinases. J Biol Chem 278:9142–9149PubMedCrossRef Mineo C, Yuhanna IS, Quon MJ, Shaul PW (2003) High density lipoprotein-induced endothelial nitric-oxide synthase activation is mediated by Akt and MAP kinases. J Biol Chem 278:9142–9149PubMedCrossRef
25.
go back to reference Nofer JR, van der Giet M, Tölle M et al (2004) HDL induces NO-dependent relaxation via lysophospholipid receptor S1P3. J Clin Invest 113:569–581PubMed Nofer JR, van der Giet M, Tölle M et al (2004) HDL induces NO-dependent relaxation via lysophospholipid receptor S1P3. J Clin Invest 113:569–581PubMed
26.
go back to reference Kuvin JT, Rämet ME, Patel AR, Pandian NG, Mendelson ME, Karas RH (2002) A novel mechanism for the beneficial vascular effects of high-density lipoprotein cholesterol: enhanced vasorelaxation and increased endothelial nitric oxide synthase expression. Am Heart J 144:165–172PubMedCrossRef Kuvin JT, Rämet ME, Patel AR, Pandian NG, Mendelson ME, Karas RH (2002) A novel mechanism for the beneficial vascular effects of high-density lipoprotein cholesterol: enhanced vasorelaxation and increased endothelial nitric oxide synthase expression. Am Heart J 144:165–172PubMedCrossRef
27.
go back to reference Hansel B, Giral P, Nobecourt E et al (2004) Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity. J Clin Endocrinol Metab 89:4963–4971PubMedCrossRef Hansel B, Giral P, Nobecourt E et al (2004) Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity. J Clin Endocrinol Metab 89:4963–4971PubMedCrossRef
28.
go back to reference Nobecourt E, Jacqueminet S, Hansel B et al (2005) Defective antioxidative activity of small dense HDL3 particles in type 2 diabetes: relationship to elevated oxidative stress and hyperglycaemia. Diabetologia 48:529–538PubMedCrossRef Nobecourt E, Jacqueminet S, Hansel B et al (2005) Defective antioxidative activity of small dense HDL3 particles in type 2 diabetes: relationship to elevated oxidative stress and hyperglycaemia. Diabetologia 48:529–538PubMedCrossRef
29.
go back to reference Kopprasch S, Pietzsch J, Kuhlisch E, Graessler J (2003) Lack of association between serum paraoxonase 1 activities and increased oxidized low-density lipoprotein levels in impaired glucose tolerance and newly diagnosed diabetes mellitus. J Clin Endocrinol Metab 88:1711–1716PubMedCrossRef Kopprasch S, Pietzsch J, Kuhlisch E, Graessler J (2003) Lack of association between serum paraoxonase 1 activities and increased oxidized low-density lipoprotein levels in impaired glucose tolerance and newly diagnosed diabetes mellitus. J Clin Endocrinol Metab 88:1711–1716PubMedCrossRef
30.
go back to reference Thomas MJ, Chen Q, Zabalawi M et al (2001) Is the oxidation of high-density lipoprotein lipids different than the oxidation of low-density lipoprotein lipids? Biochemistry 13:1719–1724CrossRef Thomas MJ, Chen Q, Zabalawi M et al (2001) Is the oxidation of high-density lipoprotein lipids different than the oxidation of low-density lipoprotein lipids? Biochemistry 13:1719–1724CrossRef
31.
go back to reference Curtiss LK, Bonnet DJ, Rye KA (2000) The conformation of apolipoprotein A-I in high-density lipoproteins is influenced by core lipid composition and particle size: a surface plasmon resonance study. Biochemistry 39:5712–5721PubMedCrossRef Curtiss LK, Bonnet DJ, Rye KA (2000) The conformation of apolipoprotein A-I in high-density lipoproteins is influenced by core lipid composition and particle size: a surface plasmon resonance study. Biochemistry 39:5712–5721PubMedCrossRef
32.
go back to reference Braschi S, Coffill CR, Neville TA, Hutt DM, Sparks DL (2001) Effect of acylglyceride content on the structure and function of reconstituted high density lipoprotein particles. J Lipid Res 42:79–87PubMed Braschi S, Coffill CR, Neville TA, Hutt DM, Sparks DL (2001) Effect of acylglyceride content on the structure and function of reconstituted high density lipoprotein particles. J Lipid Res 42:79–87PubMed
Metadata
Title
Inability of HDL from type 2 diabetic patients to counteract the inhibitory effect of oxidised LDL on endothelium-dependent vasorelaxation
Authors
L. Perségol
B. Vergès
M. Foissac
P. Gambert
L. Duvillard
Publication date
01-06-2006
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 6/2006
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-006-0244-1

Other articles of this Issue 6/2006

Diabetologia 6/2006 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.